Niktimvo is approved for treatment of chronic graft-versus-host disease. Incyte and its partner developer forecast that it may earn $650 million in net profit.
Hervé Hoppenot, president and CEO of Delaware’s pioneering biopharmaceutical company Incyte who has helped guide the company to new heights, has been named the 2024 Pete du Pont Freedom Award honoree.
Two biotech powerhouses joined forces in January 2024, when Delaware-based Incyte teamed up with Agilent, a leader in the field of companion diagnostic assays to detect biomarkers of disease, to support the development and commercialization ...
Incyte has closed the deal on a $750 million pharmaceutical company with two drug treatments in the development phase in its portfolio.
Incyte is reportedly closing on buying 1100 N. King Street and 1100 N. French Street in downtown Wilmington as its latest stage of expansion efforts. The move will bring eventually 800 people to downtown Wilmington.
Incyte has signed a deal with China Medical System Holdings Limited on povorcitinib. Terms of the deal were not disclosed.
Incyte Chairman & CEO Hervé Hoppenot has overseen Incyte’s move into the dermatological sector, developing Opzelura, the first drug approved to treat vitiligo.
After collaborating with MorphoSys on a developing cancer treatment Monjuvi, Incyte has bought full rights to develop the immunotherapy and bring it to market.
Agilent Technologies and Incyte have signed an agreement to create companion diagnostics tests, bringing the two Delaware companies together in the future of cancer treatments.
Incyte told investors two months ago that it no longer believed its $50 million deal with the Wilmington Friends School would proceed.
Incyte CEO Hervé Hoppenot will be the keynote speaker of the 2024 Delaware State Chamber of Commerce Annual Dinner in January.
Ever since Incyte's Opzelura was approved for eczema and vitiligo treatments, the drug firm has invested more resources into dermatology.
A new daylong conference known as “Delaware’s DNA” will showcase Delaware’s growing life science sector, expecting to draw people from across the country.
WILMINGTON – Seeking to grow its international market for a skin cream that can treat a variety of conditions from eczema to vitiligo, Incyte has signed a collaboration and license […]
WILMINGTON – Biopharmaceutical firm Incyte announced Monday that it has signed a clinical trial collaboration and supply agreement with a California-based firm to study the combination of their drugs in […]
WILMINGTON – Growing Wilmington-area biopharmaceutical firm Incyte has agreed to acquire a North Carolina-based firm working on a new treatment for the skin pigmentation disorder vitiligo in a deal worth […]
WILMINGTON – Incyte secured on Monday the first U.S. Food & Drug Administration approval for a treatment of the skin pigmentation disorder vitiligo, demonstrating the growing strength of the biopharmaceutical […]
When Hervé Hoppenot decided to leave his job as president of Swiss-American pharmaceutical giant Novartis’ oncology program to lead Wilmington-based Incyte, it was then a burgeoning firm with big plans. […]
Delaware is fortunate to be home to a vibrant, dynamic bioscience community. The work we do here – innovative research and development, cutting-edge science and creating and manufacturing medicines and […]
Premier Digital Partners
© 2024 Delaware Business Times
